Open Label, Multi-center, Phase I Study of TECLens Quantitative Refractive Crosslinking in Presbyopia-Aged Patients.

ConditionPresbyopia

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age40-65

SponsorTECLens, Inc.

About this trial

An 'on-eye' UV delivery system for corneal crosslinking can be used safely and effectively to help free presbyopic patients from the need for reading glasses.

Eligibility criteria

Qualifiers

Adults aged 40-65 years

Healthy cornea

Refractive error between +4.0 D and -5.0 D

Phakic or monofocal pseudophakic (≥6 months post IOL placement)

Disqualifiers

Corneal dystrophy, scarring, or prior corneal crosslinking

Astigmatism >1.0 D

Active ocular infection, inflammation, or uncontrolled dry eye

Advanced glaucoma or diabetic retinopathy

Trial design

Treatments tested in this trial

Quantitative refractive crosslinking

Treatment groups

25 Participants

are divided into 1 treatment group

Sponsors and collaborators

TECLens, Inc.

Lead sponsor

Robert Ang, MD

Collaborator

Robert Ang, MD - Asian Eye Institute

Collaborator

Source ClinicalTrials.gov